about us


Since our founding in 2003, Aprecia’s vision is to be the global leader in new technologies that address unmet healthcare needs leveraging commercial scale 3DP for pharmaceutical manufacturing. We’re committed to creating new solutions by developing pharma-ready innovations and complementary technology platforms that enable patient-centric products and help take medicine to its fullest potential.


At Aprecia, we strive every day to imagine, inspire, and transform the new age of digital medicine.

Aprecia is a unique drug delivery technology platform company that’s committed to transforming the patient and caregiver experience by reducing pill burden or simply making medicines easier to take. We imagine a world where medications are no longer challenging for patients to take or for caregivers to give. And we inspire each other every day to seek innovative solutions that address administration and adherence needs.

Built upon our proprietary three-dimensional printing (3DP)technology platform, we focus on opportunities where there is a need for medicines that are easy to take. Aprecia is the first and only company in the world utilizing this cutting-edge 3DP technology platform to develop and manufacture pharmaceutical products on a commercial scale and with an FDA approved product. We believe our platforms will generate multiple product-enhancing drug delivery technologies that can be used across all therapeutic categories. ZipDose® Technology is uniquely able to accommodate a high dosage load (over 1000 mg of active pharmaceutical ingredient) in a rapidly orodispersible tablet with a wide range of taste masking capabilities. With these capabilities, ZipDose Technology is redefining the fast-melt market.

Tablet with bubbles floating up from it


New solutions and new possibilities for patients and caregivers in the new digital age of medicine

Drawing of male torso with target circles


Never stop exploring ways to take medicine to its fullest potential

Drawing of pill bottle with upward arrow


Establish 3DP technology as a true digital pharmaceutical manufacturing technology


Aprecia is a privately held pharmaceutical technology company led by a seasoned, highly motivated team of individuals who have been contributing to the advancement of pharmaceuticals over the course of their careers.

E. Thomas Arington



Mr. Arington has served as a member of the Aprecia Pharmaceuticals Board of Directors since 2010 and as Chairman of the Board since 2011. His vision for three-dimensional printing in pharmaceuticals spans more than 20 years. Mr. Arington has spent his lifetime in the pharmaceutical industry, significantly contributing to the advancement of pharmaceuticals in multiple companies and roles.

  • Founder and Chairman of Prasco
  • Former Chairman and CEO of Duramed Pharmaceuticals, Inc.
  • Former Chairman and CEO of MarketMaster
  • 17 years with Lederle, including senior management positions

Owen Murray

Chief Executive Officer


Mr. Murray was named Chief Executive Officer in January 2023. Mr. Murray most recently served as the Vice President of North American Technical Operations and Quality Assurance at Recordati Rare Diseases in New Jersey. Prior to joining Recordati, he held varying positions of increasing responsibility at Cardinal Health, Lundbeck, and Ovation Pharmaceuticals in Europe and the United States.

Mr. Murray has more than 25 years of experience in pharmaceutical and healthcare businesses, ranging from early product development through commercialization. He has successfully developed and led R&D, operations, supply chain, and quality operations teams. Murray received his B.Sc. in Biochemistry from the University of Wales, Swansea. He earned his MBA from Seton Hall University and his MS in healthcare leadership from Brown University. Murray holds 87 international patents.

Kyle Smith, MBA

President & Chief Operating Officer


Kyle Smith was named President and Chief Operating Officer in October 2021. Mr. Smith is a 10-year veteran with Aprecia and most recently served as Vice President of Operations. Mr. Smith is responsible for leading day-to-day business activities. Mr. Smith holds a Master of Business Administration degree from Miami University, and a Bachelor of Science in Chemical Engineering from Georgia Institute of Technology.

Michael Rohlfs

Chief Financial Officer & SVP of Business Operations


Mr. Rohlfs has served as Aprecia’s Chief Financial Officer since July 2013 and brings over 20 years of experience in the pharmaceutical industry.  Mr. Rohlfs’ career has been focused in the areas of strategic planning, finance, business operations and business analytics while serving in progressive management and leadership roles including:

  • Vice President of Business Development Services at Prasco Laboratories
  • Plant Controller at Barr Laboratories
  • Director of Planning & Budget at Duramed Pharmaceuticals

Donald Wetherhold

Senior Executive Advisor & SVP


Mr. Wetherhold brings 30 years of experience in the pharmaceutical and healthcare industry, and today serves as a key strategist and advisor to the senior executive team at Aprecia. Mr. Wetherhold previously served as the company’s Chief Executive Officer (2013 – 2017) and has held numerous leadership positions across the pharmaceutical value chain throughout his career.

  • Senior Vice President, Long-Term Care at Omnicare, Inc.
  • Advisor to the Chairman at Prasco
  • Senior Vice President and General Manager of Hampton-Laine, Prasco's branded pharmaceutical business
  • President of RxPedite LLC
  • President of Sales and Marketing Services at Cardinal Health, Inc.

Kathi Rinesmith, R.Ph., MS

Senior Vice President of Regulatory Affairs


Mrs. Rinesmith serves as Aprecia's Senior Vice President of Regulatory Affairs, where she will lead the company’s regulatory strategy, objectives, policies,and programs pertaining to the company's marketed and pipeline products. Her more than 30 years of experience spans the development and registration of pharmaceutical products from early to late-stage product development, during which she has demonstrated success leading sponsor teams at FDA meetings and through the registration review process with the FDA for new product approvals.  In addition, she’s been responsible for product life-cycle management, fulfillment of product post-approval reporting obligations and global pharmacovigilance for commercial products as well as those in development. She has also contributed toward industry initiatives to develop science-based approaches to regulation by serving on a past Product Quality Research Institute (PQRI) Packaging Committee, by serving on a USP Expert Committee for Pharmaceutical Dosage Forms for a 5-year term and by providing industry feedback on draft FDA guidance documents.  Previously, Mrs. Rinesmith held senior executive product development and regulatory roles at:

  • Camargo Pharmaceutical Services
  • Prasco Laboratories
  • Barr Labs
  • Duramed Pharmaceuticals

Mike Gosselin, ph.d

Vice President of Pharmaceutical Development


Dr. Gosselin serves as Aprecia's Vice President of Pharmaceutical Development, where he will oversee product development from early innovation to commercial production at Aprecia’s 3DP Center of Excellence in Blue Ash, Ohio. Dr. Gosselin is an experienced executive with 20 years managing people and projects in pharmaceutical development and manufacturing operations. He is well experienced in dosage formulation and process development, scale-up, validation, and manufacturing for solid oral, liquid, and liquid-fill capsule products.

    Garry Hedgepeth

    Vice President of Quality


    Mr. Hedgepeth serves as Aprecia's Vice President of Quality, where he will lead the company's Quality oversight of all product development and manufacturing at Aprecia’s 3DP Center of Excellence in Blue Ash, Ohio. Mr. Hedgepeth brings more than 20 years of solid oral dose and sterile injectable experience in Quality and Operations. Additionally, Mr. Hedgepeth’s extensive background includes hosting regulatory (FDA and RoW) inspections and CMO partner audits.

      Mahendra Patel, Ph.D.

      Scientific Advisor

      MoRE INFO

      Dr. Mahendra Patel has been a key scientific advisor to Aprecia since 2003. Along with Mr. E Thomas Arington, Dr. Patel has shared a vision for the future of pharmaceutical manufacturing. His expertise has been instrumental in product and equipment design through commercial viability. Dr. Patel’s career includes strategic roles across the industry including:

      • President of Navinta
      • Former CSO of Sandoz
      • Former CEO of CorMedix
      • Co-founder and former VP of Invamed